S-1, an oral fluoropyrimidine anti-cancer agent, enhanced radiosensitivity in a human oral cancer cell line in vivo and in vitro: involvement possibility of inhibition of survival signal, Akt/PKB
S-1, an oral fluoropyrimidine anti-cancer agent, enhanced radiosensitivity in a human oral cancer cell line in vivo and in vitro: involvement possibility of inhibition of survival signal, Akt/PKB
复制标题
DOI：
10.1016/j.canlet.2004.12.048
复制
发表时间：
2005-08-26
期刊：
影响因子：
9.7
通讯作者：
Sato, M
中科院分区：
文献类型：
--
作者：
Harada, K;Kawaguchi, S;Sato, M
旨在检查口服氟嘧啶抗癌剂 (S-1) 对人类口腔癌细胞系放射敏感性的影响，重点关注对生存信号 Akt/PKB 的抑制。使用人口腔细胞癌细胞系B88。免疫组化检测体内Akt/PKB的激活情况，TUNEL法检测细胞凋亡。通过Western blot和ELISA研究Akt/PKB的体外激活，并通过Hoechst 33258染色检测凋亡细胞。 S-1（10 mg/kg/天或 50 μg/ml）通过抑制 Akt/PKB 的激活，大大增强了 B88 细胞的放射敏感性。在S-1处理的B88细胞中观察到凋亡细胞的百分比显着增加。生存信号 Akt/PKB 可能参与放射敏感性的确定。 S-1是一种口服氟嘧啶类抗癌药，通过抑制Akt/PKB的活化而发挥增强放射作用。 (C) 2005 Elsevier Ireland Ltd. 保留所有权利。
To examine the effect of an oral fluoropyrimidine anti-cancer agent (S-1) on the radiosensitivity of a human oral cancer cell line with focusing on inhibition of survival signal, Akt/PKB. A human oral cell cancer cell line B88 was used. Activation of Akt/PKB in vivo was examined by immunohistochemistry, and apoptotic cells were detected by TUNEL method. Activation of Akt/PKB in vitro was investigated by Western blot and ELISA, and apoptotic cells were detected by Hoechst 33258 staining. S-1 (10 mg/kg/day or 50 mu g/ml) greatly enhanced radiosensitivity in B88 cells by suppressing the activation of Akt/PKB. Significant increase in the percentage of apoptotic cells was observed in S-1 treated B88 cells. Survival signals Akt/PKB may be involved in determining radiosensitivity. S-1, an oral fluoropyrimidine anti-cancer agent can exert the enhancing effect on radiation by suppressing the activation of Akt/PKB. (C) 2005 Elsevier Ireland Ltd. All rights reserved.